Abstract
In the past decades, the incidence of cancer keeps its rapid increasing step all over the world and cancer is always an important threat to public health. It is believed that cancer is resulted from a series of genetic alterations leading to progressive disorder of the normal mechanisms controlling cell proliferation, differentiation, death, and/or genomic stability. The response of the cell to genetic injury and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are therefore essential in preventing tumor initiation and progression. From the same viewpoint, the relative role of DNA repair as a biomarker for prognosis, predicator of drug and therapy responses, or indeed as target for novel gene therapy is recently patented and very promising. In this review, we have summarized the studies investigating the association between XRCC4, one of the NHEJ genes, and the susceptibility to multiple cancers, and discussed its role in carcinogenesis and application in anticancer drug discovery.
Keywords: XRCC4, polymorphism, cancer, carcinogenesis
Recent Patents on Anti-Cancer Drug Discovery
Title: The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Volume: 3 Issue: 3
Author(s): Cheng-Nan Wu, Shiu-Yun Liang, Chia-Wen Tsai and Da-Tian Bau
Affiliation:
Keywords: XRCC4, polymorphism, cancer, carcinogenesis
Abstract: In the past decades, the incidence of cancer keeps its rapid increasing step all over the world and cancer is always an important threat to public health. It is believed that cancer is resulted from a series of genetic alterations leading to progressive disorder of the normal mechanisms controlling cell proliferation, differentiation, death, and/or genomic stability. The response of the cell to genetic injury and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are therefore essential in preventing tumor initiation and progression. From the same viewpoint, the relative role of DNA repair as a biomarker for prognosis, predicator of drug and therapy responses, or indeed as target for novel gene therapy is recently patented and very promising. In this review, we have summarized the studies investigating the association between XRCC4, one of the NHEJ genes, and the susceptibility to multiple cancers, and discussed its role in carcinogenesis and application in anticancer drug discovery.
Export Options
About this article
Cite this article as:
Wu Cheng-Nan, Liang Shiu-Yun, Tsai Chia-Wen and Bau Da-Tian, The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242304
DOI https://dx.doi.org/10.2174/157489208786242304 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Current Drug Therapy for Prostate Cancer: An Overview
Current Medicinal Chemistry - Anti-Cancer Agents The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets Extracellular Citrate in Health and Disease
Current Molecular Medicine Disposition of Vorinostat, A Novel Histone Deacetylase Inhibitor and Anticancer Agent, in Preclinical Species
Drug Metabolism Letters Medicinal Plants for the Prevention and Treatment of Bacterial Infections
Current Pharmaceutical Design Management of Vulvar Cancer
Reviews on Recent Clinical Trials Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
Current Cancer Drug Targets Microbial Lifestyle and Genome Signatures
Current Genomics Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis
Current Molecular Pharmacology Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design Patent Selections
Recent Patents on DNA & Gene Sequences Selective Photodynamic Effects on Breast Cancer Cells Provided by p123 Pluronic®- Based Nanoparticles Modulating Hypericin Delivery
Anti-Cancer Agents in Medicinal Chemistry Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Current Medicinal Chemistry Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma
Current Cancer Drug Targets Comparison of Large Proteomic Datasets
Current Proteomics Improved Pharmacokinetic Profile and Anti-Inflammatory Property of a Novel Curcumin Derivative, A50
Letters in Drug Design & Discovery